The proposed acquisition of GN Hearing by Amplifon, valued at €2.3 billion (approximately US$2.64 billion at the time of the announcement), stands as a monumental transaction set to fundamentally restructure the competitive environment within the global hearing aid industry, particularly impacting the United States market. Announced on March 19, 2026, this deal signifies a transformative shift for both companies, catapulting Amplifon from its position as the world’s largest hearing aid retailer into a formidable vertically integrated entity, while allowing GN to divest its hearing healthcare division and strategically refocus on its core audio, video, and gaming segments.
A Seismic Shift in Industry Structure
For decades, the hearing aid industry has been characterized by a complex interplay of a few major manufacturers and a fragmented retail landscape. Amplifon, with its vast global network of retail outlets including the prominent Miracle-Ear brand in the U.S., has long been a dominant force in distribution. GN Hearing, conversely, has been a leading manufacturer, known for its innovative technology and a portfolio of strong brands like ReSound and Beltone. The integration of these two giants marks a significant "backward integration" move, where a distributor acquires a manufacturing arm, a rarity in its scale within this sector, as noted by industry veterans.
The implications are far-reaching. Amplifon will gain direct control over the manufacturing process, intellectual property, and product development for a significant portion of the market. This vertical integration promises potential synergies, increased control over the supply chain, and opportunities to tailor products specifically for its retail networks. For GN, the sale allows it to shed its hearing healthcare business, which has been a part of its diversified technology group, and concentrate resources on its audio-visual and gaming divisions, particularly following its substantial investment in the SteelSeries acquisition. This pivot is expected to provide GN with deployable cash and a sizable equity stake in Amplifon, positioning it as a more focused, albeit potentially more cyclical, technology company.
Unpacking the Deal: Assets and Financials
The assets included in the sale are comprehensive, encompassing GN’s entire hearing business. This includes well-known hearing aid brands such as ReSound, Beltone, Jabra Enhance, Interton, and Danavox/Danalogic. Crucially, the deal also transfers related hearing intellectual property (IP), research and development (R&D) capabilities, manufacturing facilities, operational infrastructure, and the vital Beltone network partnerships. Notably, GN will retain its position in NationsHearing, an aspect it is expected to divest sometime after the Amplifon acquisition is finalized, further streamlining its exit from the hearing healthcare sector.
Amplifon’s existing empire is already vast, comprising the extensive Amplifon and Miracle-Ear retail networks, the Amplifon Hearing Health Care benefits division in the U.S., and major branded chains like GAES and Beter Horen in various international markets. The combined entity resulting from this acquisition is projected to generate approximately €3.3 billion (about US$3.8 billion) in annual revenue. This scale is expected to solidify Amplifon’s position as an "integrated leader" in audiology, a term frequently used by the company to describe its new strategic posture.
)
The Element of Surprise: Why Amplifon, Not Demant?
The announcement sent ripples of surprise throughout the hearing industry. While industry observers had widely anticipated further consolidation, few predicted Amplifon as the acquirer of GN Hearing. The consensus had long favored Demant, the world’s second-largest hearing aid company and owner of the esteemed Oticon brand, as the most logical suitor. Demant’s corporate culture and geographical proximity to GN Hearing’s headquarters near Copenhagen, just four miles apart, fostered expectations of a natural alignment. Moreover, Demant holds a significant 12% stake in GN shares, leading many to believe it would be in a prime position to make such a move or even block a rival bid. However, reports from MedWatch indicated that Demant was likely not in a legal position to obstruct the Amplifon deal, underscoring the unexpected nature of the transaction.
Niels Granholm-Leth, a veteran market analyst based in Copenhagen with DNB Carnegie, succinctly captured the industry’s sentiment, telling HearingTracker, "Forward integration [a manufacturer buying a distributor] mostly happens in tiny steps, and most people never hear about them. This backward integration step will reshape the global hearing care industry." His assessment highlights the unprecedented scale and directional shift of Amplifon’s move.
U.S. Market Dynamics: Rivals Under One Roof
One of the most immediate and impactful consequences of the acquisition in the U.S. market is the unification of two historically fierce rivals: Miracle-Ear and Beltone. These networks have competed vigorously since their respective foundings in the 1940s—Miracle-Ear by Kenneth Dahlberg in Minneapolis and Beltone by the Posen family in Chicago. Both brands built strong national identities through local offices, distinctive branding, and carefully managed product ecosystems.
)
Today, Miracle-Ear operates roughly 1,600 U.S. locations, while Beltone maintains approximately 1,200-1,350. The acquisition will bring nearly 3,000 U.S. points of sale under a single corporate umbrella, a figure that does not even include Amplifon’s broader managed care hearing-benefits division, Amplifon Hearing Health Care. This consolidation of retail presence is unparalleled.
However, the networks possess distinct operational structures. Miracle-Ear operates a hybrid model, with public filings indicating approximately 400 company-owned U.S. offices alongside about 1,200 franchised locations. Beltone, by contrast, largely functions as an independent franchisee-owner network. This structural difference presents a significant integration challenge.
Michael Andreozzi, former owner of one of the nation’s largest Beltone networks and current president of the International Hearing Society (IHS), emphasized the importance of preserving Beltone’s independent, community-based strengths. He stated to HearingTracker, "From a Beltone perspective, the dealer network has always been a very strong model because it combines local ownership with world-class technology and product innovation. Having spent many years earlier in my career as a Miracle-Ear franchise owner, I’ve seen firsthand how powerful the combination of brand marketing, advanced hearing solutions, and strong local relationships can be for patients and communities. Beltone providers bring that same level of innovation and care into their markets every day. Going forward, the opportunity will be making sure that model continues to thrive alongside Amplifon’s corporate retail presence—leveraging the strength of the products while maintaining the personalized care and clinical expertise that independent Beltone offices are known for." His comments underscore the delicate balancing act Amplifon must perform to avoid alienating a valuable network.
)
Market Share and Strategic Value
Estimates from Niels Granholm-Leth suggest that Miracle-Ear’s 1,600 stores and Beltone’s 1,350 stores collectively account for approximately 650,000 units annually. This implies a combined market share of roughly 12% of the U.S. prescription hearing aid market, or around 14% when excluding the Department of Veterans Affairs (VA) channel. Brandon Sawalich, President and CEO of Starkey, the only U.S.-headquartered global manufacturer, offered a similar estimate of "about 15%." These figures position the combined Amplifon-Beltone enterprise within striking distance of the nation’s two largest hearing aid distributors: the VA (estimated at ≥19%) and Costco (estimated at ≥16%).
While these market share figures are substantial, they also suggest a relatively modest unit volume per office for both Miracle-Ear and Beltone. This implies that the core strategic value of the deal extends beyond merely gaining raw market share. Instead, it lies significantly in Amplifon’s ability to control supply and capture a larger portion of the hearing care value chain, from manufacturing to fitting. This move is consistent with Amplifon’s stated goal of achieving €60-80 million (US$69-92 million) in annual synergies by the end of 2029, primarily driven by "insourcing" hearing aid volumes that it currently procures from external suppliers. The objective is clear: to optimize economics from the factory floor to the patient’s fitting room.
Industry Reactions and Integration Challenges
Brandon Sawalich of Starkey, while acknowledging the long-term significance of the transaction, cautioned against immediate market-altering expectations in North America. He told HearingTracker that the ultimate outcome would depend less on the announcement itself and more on Amplifon’s ability to successfully integrate a technology manufacturer into a retailer-led organization, which inherently possesses a very different operating culture. "The press release is the easy part," Sawalich stated, likening it to announcing a game schedule before it has been played. The real challenge, he emphasized, will be the arduous task of integrating cultures, business systems, leadership, and talent across two distinct organizational philosophies.
)
The acquisition also poses potential headwinds for Miracle-Ear’s current major suppliers, which primarily include Sonova, Demant, and Starkey. As Amplifon gradually shifts more of its volume toward GN-built products, these manufacturers could see a reduction in sales. Bernstein analysts Susannah Ludwig and colleagues projected that this shift could affect 2-4% of Sonova’s and Demant’s sales over time. While Starkey is privately held and does not disclose sales figures, Sawalich acknowledged that their volume supplied to Miracle-Ear was not insubstantial.
Amplifon has publicly committed to preserving GN Hearing’s identity, brands, and core capabilities within the combined organization. This commitment is vital, as there is potential for significant backlash from independent hearing care providers. Some providers have already voiced concerns on platforms like LinkedIn, questioning whether GN, historically seen as a manufacturer committed to supplying independent practices, will maintain that stance under Amplifon’s ownership. If this sentiment becomes widespread, GN could lose goodwill among independent providers, potentially opening doors for rival manufacturers to capture their business.
The "Threading the Needle" Challenge and Broader Implications
Granholm-Leth believes Amplifon will likely keep the Miracle-Ear and Beltone networks separate for many years. This strategy could involve continuing to use third-party suppliers for Miracle-Ear, serving to maintain brand differentiation and avoid abrupt disruptions in software, workflows, and product mix. The question of whether Amplifon can truly keep the two banners distinct, given Miracle-Ear’s hybrid ownership and Beltone’s independent franchisee model, remains a key challenge. Both networks, and indeed much of the hearing care industry, face an aging population of owners. Amplifon has reportedly been seeking to acquire more Miracle-Ear stores, aiming for greater direct control. Extending this strategy to Beltone would require even more capital, which might not be palatable to investors if it means acquiring stores the company can already influence through supply and branding relationships.
)
Sawalich’s "threading the needle" metaphor encapsulates the complexity Amplifon faces: expanding its reach, maintaining brand differentiation, preserving crucial relationships, and simultaneously building manufacturing credibility.
The Amplifon-GN deal could also erect higher barriers to entry for new players in the industry. The increasing technological sophistication of hearing aids from China and other Pacific Rim countries, exemplified by brands like Elehear, Yeasound, and Cearvol (as highlighted in a recent report from CES 2026), suggests a growing potential for these manufacturers to target the U.S. prescriptive hearing aid market. However, as the largest global hearing aid companies become more vertically integrated, it becomes increasingly challenging for new manufacturers to penetrate Western markets. They may find themselves relegated to online Over-The-Counter (OTC) sales, pharmacies, or big-box stores—channels that are often less attractive, harder to scale, and more price-sensitive within an already competitive landscape.
An under-discussed issue pertains to branding. Since GN is retaining its broader Jabra headset and enterprise-audio businesses, the Jabra hearing brand (including Jabra Enhance Select and Jabra Enhance Pro) may require licensing, restructuring, or eventual rebranding within the new Amplifon structure. Granholm-Leth suggested that GN might allow the hearing business to continue using Jabra branding in certain channels under a royalty fee for a transitional period, softening the shift, particularly for established brands at Costco and in OTC markets.
)
History offers a cautionary tale. During Phonak’s ultimately unsuccessful attempt to acquire GN ReSound in 2006-2007, GN significantly curtailed its investment in research and product development while the deal remained in limbo. For a company renowned for its groundbreaking "firsts" in hearing aid technology, this pause proved costly. When German regulators eventually blocked the transaction in 2007, ReSound had lost critical momentum, spending years playing catch-up. A similar scenario of resource distractions, talent flight, integration fatigue, and delayed product cycles could unfold if the current Amplifon transaction becomes protracted, though the antitrust landscape differs this time.
Outlook: A Reshaped Future
When asked to provide odds, Granholm-Leth estimated an approximately 80% chance of the Amplifon-GN acquisition being completed, with a lower probability of a Demant-related alternative emerging. The most likely outcome, therefore, is not a bidding war, but a profound reshaping of the hearing aid market, driven by a powerful combination of retail scale, patient access, and manufacturing control.
While the deal’s long-term implications for the global hearing aid market are expected to be substantial, its immediate impact on the U.S. market may be more gradual. As Sawalich summarized, "As I think about the U.S. market, I don’t see this changing a lot immediately. Ultimately, it’s all going to depend on the end product of what this new company becomes. It’s going to require great leadership and a clear vision to set that course, and they’re going to have to thread the needle on this one." The coming years will reveal whether Amplifon can successfully navigate these complexities and forge a truly integrated and dominant force in the global audiology sector.
